Subscribe
shutterstock_2183087279_t_schneider
T. Schneider / Shutterstock.com
23 January 2024Big PharmaLiz Hockley

Eagle Pharmaceuticals asserts new patents with trio of lawsuits over cancer drug

Complaints say Slayback, Apotex and Baxter Healthcare infringed two patents through NDAs for leukemia drug injection | Eagle patents issued in last two months expire in 2031.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Teva and Eagle try to block Bendeka generic
1 July 2021   Teva and Eagle Pharmaceuticals are suing to block a generic version of its leukemia drug Bendeka, arguing its patents still have plenty of time to run.
Americas
Fed Circuit affirms generic maker’s win over Eagle
11 May 2020   The US Court of Appeals for the Federal Circuit has affirmed a generic maker’s victory over pharmaceutical company Eagle Pharmaceuticals in a case involving cancer drug Belrapzo.
Big Pharma
Eagle Pharma launches new suit over leukaemia drug
6 February 2024   Oncology specialist seeks to block another bendamustine generic following trio of lawsuits in January | Firm filed complaint for patent infringement against Dr Reddy’s.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Fed Circuit affirms generic maker’s win over Eagle
11 May 2020   The US Court of Appeals for the Federal Circuit has affirmed a generic maker’s victory over pharmaceutical company Eagle Pharmaceuticals in a case involving cancer drug Belrapzo.
Americas
Teva and Eagle try to block Bendeka generic
1 July 2021   Teva and Eagle Pharmaceuticals are suing to block a generic version of its leukemia drug Bendeka, arguing its patents still have plenty of time to run.
Big Pharma
Eagle Pharma launches new suit over leukaemia drug
6 February 2024   Oncology specialist seeks to block another bendamustine generic following trio of lawsuits in January | Firm filed complaint for patent infringement against Dr Reddy’s.

More on this story

Americas
Fed Circuit affirms generic maker’s win over Eagle
11 May 2020   The US Court of Appeals for the Federal Circuit has affirmed a generic maker’s victory over pharmaceutical company Eagle Pharmaceuticals in a case involving cancer drug Belrapzo.
Americas
Teva and Eagle try to block Bendeka generic
1 July 2021   Teva and Eagle Pharmaceuticals are suing to block a generic version of its leukemia drug Bendeka, arguing its patents still have plenty of time to run.
Big Pharma
Eagle Pharma launches new suit over leukaemia drug
6 February 2024   Oncology specialist seeks to block another bendamustine generic following trio of lawsuits in January | Firm filed complaint for patent infringement against Dr Reddy’s.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent